Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human African trypanosomiasis-neurological aspects.

Peter G E Kennedy1

  • 1Department of Neurology, Division of Clinical Neurosciences, University of Glasgow Southern General Hospital, Institute of Neurological Sciences, Glasgow G51 4TF, Scotland, UK. P.G.Kennedy@clinmed.gla.ac.uk

Journal of Neurology
|March 17, 2006
PubMed
Summary

Human African Trypanosomiasis (HAT), or sleeping sickness, is fatal if untreated and requires better diagnostics and treatments. New non-toxic oral drugs are needed to improve patient outcomes and disease control efforts.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Insights into pathologic mechanisms occurring during serious adverse events following live zoster vaccination.

Journal of virology·2025
Same author

Immunoglobulin G and Complement as Major Players in the Neurodegeneration of Multiple Sclerosis.

Biomolecules·2024
Same author

The elusive nature of the oligoclonal bands in multiple sclerosis.

Journal of neurology·2023
Same author

The Spectrum of Neurological Manifestations of Varicella-Zoster Virus Reactivation.

Viruses·2023
Same author

Phenotype and Neuronal Cytotoxic Function of Glioblastoma Extracellular Vesicles.

Biomedicines·2022
Same author

The Possible Role of Neural Cell Apoptosis in Multiple Sclerosis.

International journal of molecular sciences·2022

Area of Science:

  • Neglected tropical diseases
  • Parasitology
  • Neurology

Background:

  • Human African Trypanosomiasis (HAT), or sleeping sickness, is a fatal parasitic disease transmitted by tsetse flies, affecting 36 sub-Saharan African countries.
  • The disease progresses through haemolymphatic and late encephalitic stages, presenting diverse neurological symptoms.
  • Accurate staging is crucial due to severe complications from melarsoprol treatment in late-stage disease.

Purpose of the Study:

  • To highlight the challenges in diagnosing and treating Human African Trypanosomiasis (HAT).
  • To emphasize the need for improved diagnostic criteria and non-toxic oral medications for HAT.
  • To underscore the importance of integrated control strategies, including reduced human-vector contact and increased resources.

Main Methods:

Related Experiment Videos

  • Review of current understanding of HAT pathogenesis and clinical presentation.
  • Analysis of diagnostic challenges, particularly CSF criteria for late-stage disease.
  • Evaluation of existing and potential therapeutic strategies, including eflornithine (DFMO).

Main Results:

  • Melarsoprol treatment for late-stage HAT carries a risk of severe post-treatment reactive encephalopathy (PTRE).
  • Lack of universal consensus on CSF criteria complicates accurate diagnosis of late-stage HAT.
  • Eflornithine (DFMO) offers an alternative for late-stage gambiense HAT, but a non-toxic oral drug for all stages is still needed.

Conclusions:

  • There is a critical need for non-toxic oral drugs for both early and late-stage HAT to simplify treatment and staging.
  • Effective HAT control requires enhanced measures to reduce tsetse fly exposure and increased financial and infrastructural support in Africa.
  • Further research into PTRE pathogenesis and development of novel therapeutic and diagnostic tools is essential for disease eradication.